Andrew S. Davis - May 20, 2021 Form 4 Insider Report for Silk Road Medical Inc (SILK)

Role
Chief Commercial Officer
Signature
/s/Mhairi Jones, by power of attorney
Stock symbol
SILK
Transactions as of
May 20, 2021
Transactions value $
-$256,974
Form type
4
Date filed
6/2/2021, 09:26 PM
Next filing
Jul 6, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SILK Common Stock Options Exercise $2.65K +1.66K +5.3% $1.60* 32.9K Jun 1, 2021 Direct F1
transaction SILK Common Stock Sale -$78.3K -1.66K -5.04% $47.23 31.2K Jun 1, 2021 Direct F1, F2
transaction SILK Common Stock Options Exercise $22.1K +4.67K +14.94% $4.73 35.9K Jun 1, 2021 Direct F1
transaction SILK Common Stock Sale -$220K -4.67K -13% $47.23 31.2K Jun 1, 2021 Direct F1, F2
transaction SILK Common Stock Award $17K +420 +1.34% $40.38 31.7K May 20, 2021 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SILK Option (right to buy) Options Exercise $0 -1.66K -5% $0.00 31.5K Jun 1, 2021 Common Stock 1.66K $1.60 Direct F1, F4
transaction SILK Option (right to buy) Options Exercise $0 -4.67K -5.54% $0.00 79.6K Jun 1, 2021 Common Stock 4.67K $4.73 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 11, 2020.
F2 This transaction was executed in multiple trades at price ranging from $46.67 to $48.32. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c).
F4 All of the shares subject to this option are fully vested and exercisable as of the date hereof.
F5 One forty-eighth of the shares subject to the option shall vest on September 1, 2017 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.